Construction and validation of a practical prognostic index for patients with metastatic breast cancer.

Yamamoto, Noboru; Watanabe, Tôru; Katsumata, Noriyuki; Omuro, Yasushi; Ando, Masashi; Fukuda, Haruhiko; Takue, Y; Narabayashi, Masaru; Adachi, Isamu; Takashima, S

doi:10.1200/jco.1998.16.7.2401

Cited by 131 publications

(92 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, none of the tumour TF-negative patients had liver metastasis, although this result is preliminary. Liver metastasis is well-known to provide a poor prognosis in breast cancer patients (Yamamoto et al, 1998). Taken together, although no difference in prognosis was observed for disease-free survival, the difference in metastatic sites between tumour TF-positive and -negative patients might result in the significant difference in prognosis for overall survival.…”

Section: mentioning

confidence: 81%

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration

Ueno¹,

Toi²,

et al. 2000

View full text Add to dashboard Cite

Tissue factor (TF), an initiator of the extrinsic coagulation cascade, is expressed in a wide range of cancer cells and plays important roles in cancer progression and metastasis. Recently, the intracellular function of TF has been revealed to be involved in cancer invasion, independent of the blood coagulation pathway. To evaluate the clinical significance of TF expression, we performed an enzyme-linked immunosorbent assay (ELISA) in the plasma of 67 breast cancer patients and immunohistochemistry in 213 breast cancer tissues. In the ELISA study, we showed an up-regulation of plasma TF concentration in breast cancer patients compared with normal controls. Immunohistochemistry demonstrated that TF was expressed in tumour cells and stromal cells and tumour TF expression closely correlated with stromal TF expression ( P = 0.0005). The concentration of plasma TF was associated with tissue TF expression in both tumour and stroma. The multivariate analysis demonstrated that tumour TF expression was an independent prognostic indicator for overall survival ( P = 0.0452). Our data show that plasma TF concentration reflects tissue TF expression and tumour TF expression can provide some predictive value for prognosis and distant metastasis, which indicates the importance of TF function in tumour progression. © 2000 Cancer Research Campaign

show abstract

Section: mentioning

confidence: 81%

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration

Ueno¹,

Toi²,

et al. 2000

View full text Add to dashboard Cite

show abstract

“…-For metastases to other organs, spread to the liver is known to associated with poor prognosis after [40,43], similarly for two metastatic foci [44][45]. Fro m CT3, liver involvement does not appear to affect survival as it was not affected at mult ivariate analysis, unlike mu ltiple metastatic foci.…”

Section: Discussionmentioning

confidence: 96%

“…-A long interval, greater than 2 years, between the diagnosis of breast cancer and metastatic relapse also favors good prognosis after CT1 [36][37].…”

Section: Discussionmentioning

confidence: 99%

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge

Vauléon

Mesbah

Laguerre³

et al. 2009

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

To cite this version:Elodie Purpose: Several lines of chemotherapy can be proposed for patients with metastatic breast cancer, but beyond the second line, agreement is lacking concerning the most appropriate therapeutic strategy. Methods:We conducted a retrospective analysis of the files of 162 patients, who had received at least three lines of chemotherapy (CT3) for metastatic breast cancer during a 5-year period (2000 to 2004), in order to analy ze management practices and search for factors affecting survival fro m CT3 and predictive factors of nonprogressive disease after CT3.Results: Multivariate analysis identified seven factors which had a positive influence on survival fro m CT3 (SBR grade I, absence of adjuvant hormone therapy, free interval ≥ 2 years, absence of cerebromeningeal metastasis before CT, unique focus at initiat ion of CT3, use of polychemotherapy for CT2, and comp lete res ponse to CT1 or CT2) and two predict ive factors of non-progressive disease (histology and drug group used for CT3).Conclusions: These factors should help determine the appropriate strategy for proposing a third line of chemotherapy.. .

show abstract

“…Construction and validation of a practical prognostic index for patients with metastatic breast cancer was reported by Yamamoto and colleagues (40). Multivariate analyses of data from 233 patients with metastatic breast cancer showed that LDH was among 5 factors prognostic for survival.…”

Section: Discussionmentioning

confidence: 99%

Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients

Brown

Cook

Lipton

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Survival is highly variable in women with bone metastases from breast cancer and prognostic factors are needed. We analyzed data from a phase III trial comparing zoledronic acid (ZOL) with pamidronate in patients with breast cancer and bone metastases to identify variables prognostic for overall survival.Experimental Design: Patients who received ZOL (n ¼ 435) with bone marker assessments and complete baseline data were included. Relative risks (RR) of death over 24 months were assessed using a stratified Cox regression analysis. A reduced model was generated using stepwise backward elimination until only significant (P < 0.05) variables remained.Results: Only 5 of 19 variables analyzed remained significantly prognostic for survival in the reduced multivariate model. These included age more than 50 years (RR 1.78-2.53, P 0.01 for each decade >50 versus 50); Functional Assessment of Cancer Therapy-General (FACT-G) score less than 65 units (P < 0.05 vs. !75 units); impaired (PS ! 1) versus fully active (PS ¼ 0) Eastern Cooperative Oncology Group (ECOG) performance status (RR 1.74, P < 0.01); prior versus no prior chemotherapy (RR 1.97; P < 0.01), and lactate dehydrogenase (LDH) levels. Lactate dehydrogenase ! upper limit of normal (ULN) but < 2 Â ULN correlated with a two-fold increased risk of death, and LDH > 2 Â ULN correlated with a six-fold increased risk of death versus LDH < ULN (P < 0.0001 for both). Baseline bone marker levels were not significantly correlated with survival after adjustment for other significant covariates.Conclusions: This retrospective analysis shows that LDH levels correlate strongly with survival in patients with bone metastases from breast cancer and confirms the relevance of previously described prognostic factors.

show abstract

Construction and validation of a practical prognostic index for patients with metastatic breast cancer.

Abstract: ADJCT, DLNs, HEP, LDH, and DFI were important prognostic factors for MBC patients. The prognostic index readily enables MBC patients to be stratified into three risk groups and is worth considering for future clinical trials.

Cited by 131 publications

References 0 publications

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge

Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients

Contact Info

Product

Resources

About